Literature DB >> 27394136

Thermo-sensitive hydrogel for preventing bowel injury in percutaneous renal radiofrequency ablation.

Xin Wang1, Xiaozhi Zhao1, Tingsheng Lin1, Hongqian Guo2.   

Abstract

PURPOSE: Percutaneous radiofrequency ablation (PRFA) has been used to ablate renal neoplasms with good outcome. However, if bowel lies adjacent to a tumor, ablation increases the risk of thermal bowel injury, and the consequences could be fatal. We describe the technique, effectiveness and safety of using thermo-sensitive hydrogel as insulation to displace the bowel away during PRFA.
MATERIALS AND METHODS: The study was divided into two main parts: the in vitro and in vivo studies. In in vitro study, to explore the heat insulation of hydrogel, the rabbit kidney was entirely embedded in hydrogel, and then radiofrequency ablation was performed; the temperature on the gel-air and gel-kidney interfaces was measured. In in vivo study, hydrogel of poloxamer 407, 25 % concentration (w/v), was instilled into the perinephric space of 10 rabbits under CT guidance to separate the kidney from adjacent bowel before PRFA performed in the targeted parenchyma in the gel group. For the control group, PRFA was performed in similar portions of 10 rabbits without instillation of hydrogel. Some parameters were recorded such as kidney-to-bowel and electrode-to-bowel distance. Immediately after PRFA, distribution of hydrogel was evaluated and the dimension of radiofrequency ablation zone was measured; bowel thermal injury was compared between the gel and control groups by gross anatomy and histopathological examination. To assess safety, two additional follow-up groups with 10 rabbits in each were set; after PRFA, CT scan was performed every 2 days; gel absorption, thermal damage and some other complications were evaluated during the period. RESULTS AND
CONCLUSIONS: In in vitro study, temperature was significantly lower at the gel-air than gel-kidney interface (P < .05), and the temperature gradient was positively associated with gel thickness. In in vivo study, hydrogel was instilled successfully in all rabbits in the gel group. The kidney-to-bowel and electrode-to-bowel distances were larger in the gel than control group [(1.1 ± 0.6 cm vs 0.1 ± 0.0 cm, P < .01), (1.8 ± 0.4 cm vs 0.5 ± 0.1 cm, P < .01), respectively]. The gel and control groups did not differ in size of the ablation zones (0.80 ± 0.2 cm vs 0.75 ± 0.3 cm, P > .05). Thermal injury in adjacent bowel was more serious in the control than gel group (P < .01). As for the follow-up, rabbits with gel instillation showed good condition and gel was absorbed gradually within 5 days. Those rabbits with no bowel displacement by gel got significantly lower survival rate and high complication rate (P < .01).
CONCLUSION: Hydrogel-dissection by means of thermo-sensitive hydrogel instillation is valuable for protecting the bowel adjacent to ablation area against thermal injury during PRFA.

Entities:  

Keywords:  Bowel displacement; Percutaneous radiofrequency ablation; Renal cell carcinoma; Thermal injury; Thermal-sensitive hydrogel

Mesh:

Substances:

Year:  2016        PMID: 27394136     DOI: 10.1007/s11255-016-1349-1

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  30 in total

1.  Dose-dependent hyperlipidemia in rabbits following administration of poloxamer 407 gel.

Authors:  J M Blonder; L Baird; J C Fulfs; G J Rosenthal
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

2.  Long-term outcomes after percutaneous radiofrequency ablation for renal cell carcinoma.

Authors:  Ronald J Zagoria; Joseph A Pettus; Morgan Rogers; David M Werle; David Childs; John R Leyendecker
Journal:  Urology       Date:  2011-04-13       Impact factor: 2.649

3.  In situ floating hydrogel for intravesical delivery of adriamycin without blocking urinary tract.

Authors:  Tingsheng Lin; Jinhui Wu; Xiaozhi Zhao; Huibo Lian; Ahu Yuan; Xiaolei Tang; Sai Zhao; Hongqian Guo; Yiqiao Hu
Journal:  J Pharm Sci       Date:  2014-01-21       Impact factor: 3.534

4.  Ablation of renal tumors in a rabbit model with interstitial saline-augmented radiofrequency energy: preliminary report of a new technology.

Authors:  T J Polascik; U Hamper; B R Lee; Y Dai; J Hilton; C A Magee; J K Crone; M J Shue; M Ferrell; V Trapanotto; M Adiletta; A W Partin
Journal:  Urology       Date:  1999-03       Impact factor: 2.649

5.  Defining the complications of cryoablation and radio frequency ablation of small renal tumors: a multi-institutional review.

Authors:  D Brooke Johnson; Stephen B Solomon; Li-Ming Su; Edward D Matsumoto; Louis R Kavoussi; Stephen Y Nakada; Timothy D Moon; W Bruce Shingleton; Jeffrey A Cadeddu
Journal:  J Urol       Date:  2004-09       Impact factor: 7.450

6.  Treatment of renal tumors by percutaneous ultrasound-guided radiofrequency ablation using a multitined electrode: effectiveness and complications.

Authors:  Jose L del Cura; Rosa Zabala; Jose I Iriarte; Miguel Unda
Journal:  Eur Urol       Date:  2009-11-13       Impact factor: 20.096

7.  Using an electrode as a lever to increase the distance between renal cell carcinoma and bowel during CT-guided radiofrequency ablation.

Authors:  Byung Kwan Park; Chan Kyo Kim
Journal:  Eur Radiol       Date:  2007-12-01       Impact factor: 5.315

8.  Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study.

Authors:  Tito Livraghi; Luigi Solbiati; M Franca Meloni; G Scott Gazelle; Elkan F Halpern; S Nahum Goldberg
Journal:  Radiology       Date:  2003-02       Impact factor: 11.105

9.  Application of radiofrequency ablation of renal VX2 tumors by cooled-tip electrode in a rabbit model.

Authors:  Yungjen Ho; Yongsan Huang; Chunming Lin; Chihlin Chung; Yungchang Lin
Journal:  J Endourol       Date:  2009-04       Impact factor: 2.942

10.  Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours.

Authors:  Tze M Wah; Henry C Irving; Walter Gregory; Jon Cartledge; Adrian D Joyce; Peter J Selby
Journal:  BJU Int       Date:  2013-10-22       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.